PKRA83 hydrochloride hydrate, also known as PKRA7, is a potent prokineticin (PK2) antagonist that competes with PK2 for binding to its receptors, PKR1 and PKR2. It exhibits high inhibitory affinity with IC50 values of 5.0 nM for PKR1 and 8.2 nM for PKR2, displaying anticancer, anti-arthritis, and anti-angiogenic properties. Additionally, this compound is capable of crossing the blood-brain barrier [1] [2] [3].

PKRA83（1 µg/mL）在体外有效地降低了PK2诱导的微血管内皮细胞分支形成[1]。

PKRA83 hydrochloride hydrate (20 mg/kg；腹腔注射) 在胶质母细胞瘤异种移植肿瘤模型中展现了抑制肿瘤的效能[1]。另外，PKRA83 hydrochloride hydrate (15 mg/kg；腹膜内注射，每日一次连续2周) 被发现能有效缓解小鼠胶原诱导性关节炎的症状[2]。